Mantell Associates Life Sciences division works with the Biotech, Pharmaceutical and Contract Research Organisations across the globe placing Junior to Senior level professionals with companies over a number of different therapeutic areas such as Oncology, Neurology, Dermatology, with early stage start up Biotech companies as well as some of the biggest Pharmaceutical names in the industry. As well as that, the Life Sciences team also represents Preclinical up to phase 4 CROs. The industry continues to grow with exciting and busy times ahead with huge investments across the board, and our expansion also takes us into new hires for 2022 in the US, as well as Switzerland. See below some of the most notable movements that have happened in Q3 and Q4…

​

Maciek Mikucki, Group CFO

Moved to: Polpharma Group

Moved from: Provident Polska

Sector: Pharmaceutical

In his new role as Group Chief Financial Officer at Polpharma Group, Maciek brings with him a wealth of knowledge from a career that spans over 25 years with some of the most recognisable names in the world. His previous posts were at companies including Reckitt Beckinser, The Coco-Cola Company, Ipsos and Teva Pharmaceuticals, just to name a few, and most recently worked at Provident Polska. Mantell Associates has successfully placed Maciek in his new role as the Group Chief Financial Officer at Polpharma Group where he will be leading financial decisions for the business globally.

​

Padma Kodukala, Chief Business Officer

Moved to: A-Alpha Bio

Moved from: Precision NanaSystems inc.

Sector: Biotechnology

Padma joins A-Alpha Bio as Chief Business Officer, bringing with her a wealth of Commercial experience across Project Management, Business Development, Strategy and Licensing. This experience comes from a career that spans for over 20 years with some of the most renowned names in the Pharmaceutical and Life Sciences sector such as Pfizer, Life Technologies, and the likes of Beckett Dickinson. She joins A-Alpha Bio as Chief Business Officer and as the Commercial professional for the organisation to spearhead customer growth and build essential partnerships for the business.

​

Michael Soldan, Chief Executive Officer

Moved to: Polpharma Group

Moved from: AB2 Bio

Sector: Pharmaceutical

Michael Soldan joins the Polpharma Group as the Chief Executive Officer with a wealth of knowledge in Biosimilars. He brings a wealth of experience to this new position, having worked previously with big names in the Life Sciences field, including Fresenius Kabi, Grunenthal, Boehringer Ingelheim and Merck Group where he was the Senior Vice President of Biosimilars. As CEO, Michael is going to be at the forefront of developing strategy and building on the already successful brand of the Polpharma Group– Mantell Associates placed him in this position, and we wish him success and all the very best.

​

Molly McGlaughlin, Chief Operating Officer

Moved to: Vigene Bioscience

Moved from: Azzur Group

Sector: Pharmaceutical

Molly McGlaughin joins theAzzur Group as a Chief Operating Officer, bringing with her over 30 years of experience in the Pharmaceutical and Manufacturing world, as well as an Bachelors and Masters degree. Her previous role was as Chief Operating Officer at Vigene Biosciences. Molly has previously led hugely successful teams in an Executive capacity at companies including Mallinckrodt, BioVectra, Selexisand Cytovance Biologics, to name a few. In her new role at Azzur Group, Molly will be at the forefront of leading best practise for the business to ensure customers’ needs are met.

​

Aamir Malik, Executive Vice President

Moved to: Pfizer

Moved from: McKinsey & Company

Sector: Biopharmaceutical

The Pharmaceutical giant Pfizer appointed Aamir Malik as Executive Vice President and Chief Business Innovation Officer in September 2021. He brings 25 years of experience from McKinsey & Company where he was heavily involved in strategy for Life Sciences firms at a huge scale. He also holds a Finance Bachelors degree from Indiana University Bloomington. In his new role, Aamir will use continue to use his Consultancy experience to trove the Commercial function of the business forward after a hugely successful year of sales in the Vaccine space, no doubt the future for Pfizer is one to keep an eye on!

​

A NOTE FROM OUR CEO: Alessandro Mantell

It is with great pride and excitement that Mantell Associates have launched our first ever ‘Movers & Shakers’, which has been designed to highlight some of the biggest moves across the Life Science & Pharmaceutical Industry within the first six months of 2021.

Anyone who has followed the Mantell Associates journey so far will see the great extent of the effort and care that we have invested into making Mantell Associates not just ‘another recruitment business’ but a truly specialist, high-level headhunting organisation. We focus on Senior level appointments and consulting services, but we strive to share market intelligence and industry relevant content, and to provide exposure for individuals and businesses through the Mantell Associates Network podcast, which has already featured 21 industry leaders. In this ‘Movers & Shakers’ we look at the high level leadership moves between January and June this year, in particular across CDMO Large Molecule, CDMO Small Molecule, Life Sciences, Medical Devices & Consultancies, Market Access, HEOR. The incredible people and businesses that we highlight in this particular ‘Movers & Shakers’ are not only those who changed role but rather those who, during an incredibly difficult time, saw an opportunity to make an impact on the world and those around them.

Thank you from all of the Mantell Associates team – we hope you enjoy it!